Chengdu Shengnuo Biopharm Co., Ltd

Chengdu Shengnuo Biopharm Co., Ltd. – Over 20 Years of Peptide Synthesis Excellence, Delivering Reliably from API to CDMO Shengnuo Biopharm is a national high-tech enterprise and a recognized "Specialized and Innovative Little Giant," listed on the STAR Market in 2021. We don’t rely on complex narratives — just two decades of solid work, scaling peptides from the lab to an annual production capacity of 4 metric tons. We have built integrated API and finished dosage production lines, established a Sino-US dual compliance system, and continue to keep our pipeline toward the global forefront. DMF-Filed Peptide APIs (Partial List) Semaglutide, Tirzepatide, Retatrutide, Liraglutide, Eptifibatide, Icatibant Acetate, Octreotide Acetate, Teriparatide, Ziconotide, Ganirelix, Linaclotide, Bivalirudin, Abaloparatide, Terlipressin Acetate. These products cover key therapeutic areas including metabolism, anticoagulation, oncology, and gastroenterology, supporting stable supply and ANDA submissions for partners. R&D Pipeline – Following the Frontier, Not Every Trend.We don’t chase every trend, but on the peptide tracks we already choose, we are committed to making our processes, capacity, and compliance truly dependable. If you are looking for a peptide partner with both experience and flexibility, we welcome further discussion. Shengnuo’s services are fully dedicated to peptides — from APIs to finished dosage forms, from CDMO services to peptide-based cosmetic and wellness products. Every step is delivered with full commitment, offering a true one-stop, end-to-end solution. We have already partnered with multiple well-known domestic pharmaceutical companies and universities, with products either already on the market or advancing through Phase II clinical trials — clear proof of Shengnuo’s technical depth and accumulated expertise.